Your shopping cart is currently empty

LT-626 is a potent PARP inhibitor with an IC50 of 1.60 nM. It effectively inhibits the synthesis of intracellular PAR, with an IC50 of 17.9 nM, and exhibits increased cytotoxicity in colorectal cancer cells harboring MRE11 mutations. In colorectal cancer cells, LT-626 shows synergistic effects when combined with Cisplatin, Oxaliplatin, and SN-38. This compound is applicable for studying colorectal cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | LT-626 is a potent PARP inhibitor with an IC50 of 1.60 nM. It effectively inhibits the synthesis of intracellular PAR, with an IC50 of 17.9 nM, and exhibits increased cytotoxicity in colorectal cancer cells harboring MRE11 mutations. In colorectal cancer cells, LT-626 shows synergistic effects when combined with Cisplatin, Oxaliplatin, and SN-38. This compound is applicable for studying colorectal cancer. |
| Molecular Weight | 379.37 |
| Formula | C20H15F2N5O |
| Cas No. | 1207456-03-8 |
| Smiles | CN1C([C@H]2C=3C4=C(N[C@@H]2C5=CC=C(F)C=C5)C=C(F)C=C4C(=O)NN3)=NC=C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.